← Back to Search

Psychological Treatment for Intrusive Thoughts

N/A
Recruiting
Led By Ryan J Jacoby, Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults ages 18-60 years old
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from week 0 (baseline) to post-treatment (week 8)
Awards & highlights

Study Summary

This trial is testing whether psychological treatment can help people with repetitive negative thinking who have trouble stopping unwanted thoughts and shifting their attention.

Who is the study for?
This trial is for adults aged 18-60 in Massachusetts with repetitive negative thinking due to OCD, GAD, or MDD. Participants must be fluent in English, right-handed, have internet access and a device with a camera and microphone. They should not be currently receiving psychotherapy or have unstable psychotropic medication use.Check my eligibility
What is being tested?
The study tests if psychological treatments can improve attention control among those who struggle to stop unwanted thoughts related to OCD, GAD, and MDD. It compares Emotion Regulation Therapy focused on Attention Regulation (AR-ERT) against Supportive Psychotherapy (SPT).See study design
What are the potential side effects?
As this is a psychological treatment study involving therapy sessions rather than medications, typical drug side effects are not expected. However, discussing emotional topics may cause temporary discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 60 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 0 (baseline) to post-treatment (week 8)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 0 (baseline) to post-treatment (week 8) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in transdiagnostic repetitive negative thinking at 8 weeks (as measured by the Perseverative Thinking Questionnaire)
Secondary outcome measures
Change from baseline in OCD symptom severity at 8 weeks (as measured by the Yale-Brown Obsessive-Compulsive Scale)
Change from baseline in depression symptom severity (as measured by the Structured Interview Guide for the Hamilton Depression Rating Scale)
Change from baseline in functional impairment (as measured by the Work and Social Adjustment Scale)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Emotion Regulation Therapy - Attention Regulation (AR-ERT)Experimental Treatment1 Intervention
Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
Group II: Supportive Psychotherapy (SPT)Active Control1 Intervention
Individuals with repetitive negative thinking receiving Supportive Psychotherapy.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,932 Previous Clinical Trials
13,198,397 Total Patients Enrolled
185 Trials studying Depression
29,556 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,785 Previous Clinical Trials
2,689,658 Total Patients Enrolled
667 Trials studying Depression
251,584 Patients Enrolled for Depression
Ryan J Jacoby, Ph.D.Principal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
144 Total Patients Enrolled

Media Library

Emotion Regulation Therapy - Attention Regulation (AR-ERT) Clinical Trial Eligibility Overview. Trial Name: NCT04225624 — N/A
Depression Research Study Groups: Supportive Psychotherapy (SPT), Emotion Regulation Therapy - Attention Regulation (AR-ERT)
Depression Clinical Trial 2023: Emotion Regulation Therapy - Attention Regulation (AR-ERT) Highlights & Side Effects. Trial Name: NCT04225624 — N/A
Emotion Regulation Therapy - Attention Regulation (AR-ERT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04225624 — N/A
Depression Patient Testimony for trial: Trial Name: NCT04225624 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any new enrollees being taken into this clinical experiment?

"Affirmative. Clinicaltrials.gov's data affirms that this trial, which was originally posted on April 30th 2021, is actively recruiting potential participants. Approximately 98 people are needed from 1 medical facility for the study to be successful."

Answered by AI

Does this research endeavor accept participants of a more advanced age?

"This study is available to adults aged 18-60."

Answered by AI

What criteria must potential participants meet to qualify for this trial?

"This clinical trial is seeking 98 volunteers who are between 18 and 60 years old, with a diagnosis of obsessive-compulsive disorder."

Answered by AI

To what extent can this medical study accommodate participants?

"Affirmative. As per the information available on clinicaltrials.gov, this medical study is actively seeking participants and was first posted in April 2021 with an update made in August 2022. The goal is to recruit 98 patients from a single site."

Answered by AI

Who else is applying?

What state do they live in?
Massachusetts
New Hampshire
What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
2

Why did patients apply to this trial?

I am greatly affected by OCD and want to help move the research forward. I think that I would benefit from the therapy.
PatientReceived no prior treatments
~18 spots leftby Dec 2024